Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI)

EuroIntervention

Volumn 9, Issue 4, 2013, Pages 501-504

  Kajiya, Takashi ^a   Liang, Michael ^a   Sharma, Ranjit Kumar ^a   Lee, Chi Hang ^a   Chan, Mark Y ^a   Tay, Edgar ^a   Chan, Koo Hui ^a   Tan, Huay Cheem ^a   Low, Adrian F ^a  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

ABSORB BVS; Bioresorbable vascular scaffold; STEMI

Indexed keywords

EVEROLIMUS;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DEVICE SAFETY; DRUG ELUTING BIOABSORBABLE VASCULAR SCAFFOLD; ELECTROENCEPHALOGRAM; FEMALE; FOLLOW UP; HEART DEATH; HEART HEMODYNAMICS; HUMAN; IATROGENIC DISEASE; INDUCED HYPOTHERMIA; MALE; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VASCULAR IMPLANT;

AGED; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; SIROLIMUS; TREATMENT OUTCOME;

EID: 84883440972     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9I4A80     Document Type: Article

References (6)

1. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-74.
2. Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, McFadden E. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. The COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58:11-8.
3. Gomez-Lara J, Brugaletta S, Farooq V, Onuma Y, Diletti R, Windecker S, Thuesen L, McClean D, Koolen J, Whitbourn R, Dudek D, Smits PC, Chevalier B, Regar E, Veldhof S, Rapoza R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv. 2011;4:1271-80.
4. Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia- Garcia HM, Ormiston JA, Serruys PW. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart. 2013;99:98-105.
5. Liang M, Kajiya T, Lee CH, Chan M, Teo SG, Chan KH, Tan HC, Low AF. Initial experience in the clinical use of everolimus-eluting bioresorbable vascular scaffold (BVS) in a single institution. Int J Cardiol. 2013 Jan 2 [Epub ahead of print].
6. Diletti R, Serruys PW, Farooq V, Sudhir K, Dorange C, Miquel- Hebert K, Veldhof S, Rapoza R, Onuma Y, Garcia-Garcia HM, Chevalier B. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164:654-63.